On August 19, BOC International (China) Co.,Ltd. announced that the company plans to inject 1.4 billion yuan into its wholly-owned subsidiary BOC International Investment Co., Ltd., increasing the subsidiary's registered capital from 600 million yuan to 2 billion yuan.
According to the announcement, this capital injection aims to support BOC International Investment's business development and aligns with the company's strategic planning. Following the capital increase, BOC International Investment will remain a wholly-owned subsidiary of the company. The transaction does not involve related party dealings nor constitute a major asset restructuring. The company's board of directors has approved the capital injection, which does not require shareholders' meeting approval.
BOC International Investment primarily engages in private equity investment fund business. According to public records, the company has cumulatively invested in 23 funds and enterprises, with 15 still in operation.
Financial reports show that as of December 31, 2024, BOC International Investment had total assets of 910 million yuan, which slightly increased to approximately 915 million yuan in the first quarter of 2025. In terms of operating revenue, the company generated 23.01 million yuan in revenue in 2024 with net profit of 9.36 million yuan, while first-quarter 2025 revenue reached 6.21 million yuan.
Securities firms typically operate private fund management business through their private equity subsidiaries, with revenue mainly derived from management fees based on assets under management and performance fees based on excess returns. In recent years, securities firms' private equity subsidiaries have developed distinctive business scopes and operating models. Beyond transitioning toward "investment + investment banking" and "sponsorship + follow-on investment" models, they also conduct equity investments using proprietary funds, meeting enterprises' financing needs while supporting real economy development and enhancing synergies between different business lines.
Industry professionals believe that "capital injections are typically based on stable profitability of subsidiaries and intentions to allocate more resources to such businesses." With recent policy encouragement, securities firms' private equity subsidiaries are expected to play larger roles in supporting key areas such as technological innovation and high-end manufacturing, as well as serving small and medium-sized enterprises.
On August 18, Chengdu Zhongke Zhuoer Intelligent Technology Group Co., Ltd. announced the completion of its Series B lead investor fund settlement. This financing round was initiated by BOC International Investment, with its Technology Innovation Collaborative Development Fund serving as the lead investor. The funds will focus on resolving capital needs for core process research and development of semiconductor lithography quartz mask substrates and key domestic production line construction, accelerating breakthroughs in mass production bottlenecks.
Comments